Top Back to top

EBMT centre members and national registries are requested to document CAR T cell therapies

by
  • The EBMT Registry allows to register patients treated with Advanced Therapy Medicinal Products (ATMPs) manufactured from hematopoietic cells, including CAR-T cells, other immune effector cells-based therapies and stem cell-based cell or gene therapies, and capture short and long-term follow-up. The Cellular Therapy Med-A form was designed to capture all essential information describing the administered drug product and patient follow-up.
  • The EBMT Registry – with the Cellular Therapy Med-A form now included - received a qualification opinion from EMA, recognizing its value to capture follow-up of patients treated with CAR-T cells.
  • EBMT urges affiliated centres to register patients treated with commercial CAR-T cells to better understand the European landscape in this emerging therapeutic area and contribute to the thorough evaluation of the medical value of these breakthrough therapies, including long-term follow-up as mandated by health authorities.
  • Registration of patients can be done in ProMISe, and will be facilitated when full migration to MACRO is achieved. Patients can be registered as soon as collection of autologous mononuclear cells is planned.
  • Registration of patients treated with investigational CAR-T cells – whether in an academia- or industry-sponsored clinical trial – will provide additional insight into European activities in the field. CAR-T cells administered in the context of the hospital exemption are of special interest to fully evaluate the importance of this provision part of the ATMP regulation for academia and industry.
  • Access to follow-up data by different stakeholders is the subject of the “Go-CART” project that brings together multiple stakeholders interested in the evaluation of CAR-T cells.
  • EBMT will provide periodic updates on the number of registered patients.

If you have any questions please contact registryhelpdesk@ebmt.org

Number of CAR-T treated patients in the Registry - September 2019

 

Map Europe - Countries reporting CAR-T cell therapies

 

Need help?

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to data.protection@ebmt.org